Kornimate/medical-research-clean huggingface dataset:
tranexamic acid as an intervention in placenta previa

Conditions: Interventional Drug in Placenta Previa

Summary: antepartum hemorrhage (aph) due to placenta previa is an important cause of worldwide perinatal mortality and maternal morbidity in pregnant women

antepartum hemorrhage (aph) due to placenta previa is an important cause of worldwide perinatal mortality and maternal morbidity in pregnant women. no medication is of specific benefit to a patient with placenta previa. tocolysis may be cautiously considered in some circumstances in order to administer antenatal corticosteroids. a review article concluded that there is no improvement in perinatal outcome with prolonged tocolytics, and tocolysis beyond 48 hours is not clinically indicated.

Eligibility criteria:
inclusion criteria: * pregnant at 28 weeks gestation and more * vaginal bleeding due to placenta previa * stable hemodynamically * accept to participate in the trial exclusion criteria: * hypersensitivity to tranexamic acid * acquired defective color vision * history of venous thromboembolism * pre-existing medical conditions (diabetes mellitus, hypertension, renal disease) * smokers * refused to participate in the trial

Keywords: placenta previa tranexamic acid intervention double blind
a study of the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders

Conditions: Schizophrenia; Bipolar Disorder; Schizoaffective Disorder

Summary: the purpose of this study is to evaluate the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders


Eligibility criteria:
inclusion criteria: * children and teens with bipolar i disorder (manic or mixed), schizophrenia or schizoaffective disorder * willingness to discontinue all antipsychotic medications during the study period exclusion criteria: * patients who are clinically stable on treatments that are well tolerated * substance-induced psychotic disorders
investigation of the effect of supporting nursing care provided in line with during intrapartum period

Conditions: Delivery;Breech;Stillbirth

Summary: aim: the aim of the research was to examine the effect of supportive nursing care provided in line with evidence-based practices during the intrapartum period.

methods design and settings this study with intervention-control group, randomized and intervention type was carried out in a hospital in balikesir, located in the west of turkiye. hypotheses hypothesis 1: supportive nursing care provided in line with evidence-based practices during the intrapartum period has an effect on the state anxiety level of women. hypothesis 2: supportive nursing care provided in line with evidence-based practices during the intrapartum period has an effect on perceived labor pain. hypothesis 3: supportive nursing care provided in the intrapartum period in line with evidence-based practices has an effect on the duration on birth. hypothesis 4: supportive nursing care provided in line with evidence-based practices in the intrapartum period has an effect on maternal satisfaction. universe and sample of the research

Eligibility criteria:
inclusion criteria: * pregnant women over 18 years of age, * with cervical dilatation 3 cm or more, * planned for spontaneous vaginal delivery, * term and singleton pregnancy, * who speak turkish, who did not have language communication problems, * who voluntarily agreed to participate in the study were included exclusion criteria: * pregnant women with head-pelvis incompatibility * those who gave birth by cesarean section before * pregnant women planned for cesarean delivery * pregnant women with any systemic disease (diabetes mellitus, hypertension, etc.) * pregnant women who develop fetal distress or hypoxia during labor)

Keywords: supportive nursing care state anxiety.
a study to evaluate the pharmacokinetics, safety, and pharmacodynamics of olpasiran in participants with various degrees of hepatic impairment

Conditions: Hepatic Impairment

Summary: the primary objective of the study is to evaluate the pharmacokinetics (pk) of a single dose of olpasiran in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.


Eligibility criteria:
inclusion criteria: * male or female participants of nonchildbearing potential, between 18 and 75 years of age (inclusive) at the time of screening. * body mass index between 18.0 and 40.0 kg/m\^2 (inclusive) at the time of screening. participants with normal hepatic function only: • in good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ecg, vital signs measurements, and clinical laboratory evaluations at screening and check-in as assessed by the investigator (or designee). participants with hepatic impairment only: • child-pugh a (group 2), b (group 3), or c (group 4) classification defined by both screening (to determine participant group) and check-in (to confirm participant group prior to dosing) clinical laboratory values and physical examination findings. exclusion criteria: * history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee). * estimated glomerular filtration rate \< 60 ml/min/1.73m\^2 (groups 1-3) or \< 50 ml/min/1.73m\^2 (group 4 only) by modification of diet in renal disease formula at screening or check-in. * receiving or has received any investigational drug within the 30 days or 5 half-lives (whichever is longer) before receiving olpasiran. * participants who were previously exposed to olpasiran. * female participants with a positive pregnancy test at screening or check-in. participants with normal hepatic function only: * positive hepatitis panel. participants whose results are compatible with prior immunization may be included. * alanine aminotransferase and aspartate aminotransferase elevations \> 3x upper limit of normal at screening or check-in. participants with hepatic impairment only: * positive for hepatitis b surface antigen. participants with positive hepatitis b core antibody may be included if hepatitis b surface antigen is negative. participants with positive hepatitis b surface antibody may be included (consistent with prior vaccination). * active malignancy of any type. participants with a history of malignancy that has been eradicated with supporting medical documentation indicating that there is no residual malignancy detected in the past 2 years will be allowed. * values outside the normal range for liver function tests that are not consistent with their hepatic condition, as determined by the investigator (or designee).

Keywords: olpasiran hepatic impairment normal hepatic function amg 890
comparing effects of 3 sources of garlic on cholesterol levels

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to determine whether fresh garlic can positively affect cholesterol in adults with moderately high cholesterol levels. this study will also determine whether the same effects can be found for two main types of garlic supplements: a dried powdered garlic (designed to yield the same effect as fresh garlic) and an aged garlic extract preparation.

garlic supplements are the most consumed herbal products in the united states. the most common health claim made for garlic supplements is cholesterol lowering activity. this claim has not been supported by recent clinical trials and meta-analyses. however, data suggest that it is not necessarily the garlic that has been ineffective, but rather the particular garlic preparations being used. to date, the predominant type of garlic preparation used in these clinical trials has been dried garlic powders. a few clinical trials have reported beneficial lipid effects using an aged garlic extract, and only a small number of inconclusive uncontrolled trials have used fresh garlic. a rigorous trial directly comparing different types of garlic preparations for their effects on serum lipids is needed. adults with moderately elevated low density lipoprotein cholesterol (ldl-c) will be randomized to one of four groups for 6 months: fresh garlic, dried powdered garlic tablets, aged garlic extract tablets, or placebo control. the fresh garlic will be provided to patients with "study sandwiches"; all other groups will receive the same study sandwiches without the garlic. all patients will take daily study tablets, but the tablet assignment will be double-blind. patients will pick up study sandwiches twice a week and study tablets once every 2 weeks for 28 weeks. blood samples will be taken once a month, with additional blood draws at the start and end of the study.

Eligibility criteria:
inclusion criteria: * ldl-c 130-190 mg/dl (fasting single sample) * bmi (body mass index) 19-30 kg/m2 (42-66 lb/m2) * weight stable for last 2 months * not actively on a weight loss plan * ethnicity representative of local population * no plans to move from the area over the next 9 months exclusion criteria: * pregnant, lactating, within 6 months postpartum, or planning to become pregnant in the next year * diabetes (type i or ii) or history of gestational diabetes * heart disease * active neoplasms * renal or liver disease * hyperthyroidism or hypothyroidism * lipid lowering medications (known to affect lipid metabolism, platelet function, or antioxidant status) * blood pressure medications * excessive alcohol intake (self reported, more than 3 drinks/day) * currently under psychiatric care or severely clinically depressed

Keywords: garlic supplements adults hypercholesterolemics randomized clinical trial
home hospital for bariatric sleeve gastrectomy

Conditions: Bariatric Surgery Candidate; Bariatric Sleeve Gastrectomy; Home Hospital

Summary: providing acute care at home for medicine patients is a well-studied care model. providing acute care at home immediately following major surgery is less well understood. the investigators seek to demonstrate the noninferiority of care at home versus the hospital for patients undergoing bariatric sleeve gastrectomy.


Eligibility criteria:
inclusion criteria: * all existing home hospital criteria apply, with the following taking precedent for this specific condition * 21-55 years old * indication for bariatric laparoscopic sleeve gastrectomy per surgeon * caregiver capable of communicating with the home hospital team and able to stay in the same home as the patient the first night the patient is home exclusion criteria: * all existing home hospital criteria apply, with the following taking precedent for this specific condition * comorbidities * body mass index\>55 * chronic kidney disease * heart failure * history of * chronic pain (with or without opioid use) * substance use disorder * venous thromboembolism * stroke * chronic headache * medications * anticoagulants and anti-platelets: aspirin, clopidogrel, warfarin, and direct oral anticoagulants * beta blockade * immunosuppressive * supplemental oxygen * allergy to ketorolac * prolonged qtc
latent tuberculosis infection in korean health care workers

Conditions: Latent Tuberculosis

Summary: the investigators aim to study the prevalence of latent tuberculosis infection (ltbi) using whole-blood interferon-r release assays, and determine the risk factors of ltbi in korean health care workers.

further study details as provided by hanyang university hospital

Eligibility criteria:
inclusion criteria: * health care workers in university affiliated hospital * adult aged 20-65 exclusion criteria: * active tuberculosis * subjects diagnosed with hiv infection, malignancy * subjects having immunosuppressive drug therapy

Keywords: latent tuberculosis interferons tuberculosis healthcare
effects of forskolin on intraocular pressure in glaucomatous patients under treatment with either beta-blockers or prostaglandins eye drops

Conditions: Primary Open Angle Glaucoma; Intraocular Pressure

Summary: elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. several drugs exist on the market that may decrease iop in glaucomatous patients. however, some patients cannot reach the target pressure despite a multitherapy with a combination of drugs, and are therefore addressed to surgical treatments. forskolin is a natural compound that is a receptor-independent adenyl-cyclase activator, that increases intracellular camp. it has been shown to be able to decrease iop after topical application, by a mechanism that is not used by the other drugs. aim of the present study is to see whether oral administration of a food supplement containing forskolin (kronek) has any effect on the iop of poag patients with stable iop obtained by treatment with either beta-blockers or prostaglandins.


Eligibility criteria:
inclusion criteria: * primary open angle glaucoma associated with ocular hypertension * target pressure achieved by single-agent therapy (beta-blockers or prostaglandins) * visual acuity \> 6/10 exclusion criteria: * miopy or hypermetropy \> 5d * concomitant ocular pathologies * previous ocular surgery * known hypersensitivity to any of the components in the kronek tablets * concomitant participation in other trials * changes of topic glaucoma therapy during the course of the study

Keywords: poag iop forskolin beta-blockers prostaglandins
the effect of risk factors considered together with preterm birth history on development

Conditions: Preterm Birth

Summary: this thesis was planned to examine the effects of risk factors seen with a history of preterm birth on sensory and motor development in preschool children. a total of 48 children, 24 with only a history of preterm birth and 24 with additional risk factors for preterm birth, were included in the study.

this thesis was planned to examine the effects of risk factors seen with a history of preterm birth on sensory and motor development in preschool children. a total of 48 children, 24 with only a history of preterm birth and 24 with additional risk factors for preterm birth, were included in the study. additional risk factors, including respiratory distress syndrome, intraventricular bleeding, periventricular leukomalacia, necrotizing enterocolitis, retinopathy of prematurity, and bronchopulmonary dysplasia, which are common in preterm infants, were recorded. peabody motor development scale-2 was used to evaluate motor development performances and dunn sensory profile was used to evaluate sensory processing.

Eligibility criteria:
inclusion criteria: 1. born before 37 weeks 2. not having a neurological diagnosis 3. to be 24-60 months old, 4. to be at a mental level to be able to understand and apply commands exclusion criteria: 1. patients with diagnosed neurological, neuromuscular, genetic disease 2. children whose parents were not willing to participate in the study were not included in the study.

Keywords: preterm risk factors sensory development motor development, pre-school
srg-514 administered intraoperatively to patients undergoing breast-conserving cancer surgery

Conditions: Breast Cancer

Summary: this is a multicenter, first-in-human (fih), open label, phase 1 dose escalation and recommended phase 2 dose (rp2d) extension trial with a primary objective to define the rp2d of srg-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. srg-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.

this is a multicenter, first-in-human (fih), open label, phase 1 dose escalation and recommended phase 2 dose (rp2d) extension trial with a primary objective to define the rp2d of srg-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. srg-514 will be investigated utilizing a 3+3 convention dose escalation cohorts, with 3 to 6 patients enrolled at each dose level, and a minimum of 6 patients enrolled at the highest dose level, for a total of approximately 12-18 patients in the dose escalation portion of the study. srg-514 doses will be escalated based on safety and potential dose-limiting toxicities (dlts) within the 14-day period following srg-514 administration. patients who do not complete the dlt period for reasons other than study drug related toxicity would be considered non-evaluable for dlt assessment and may be replaced.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * body weight \>50kg * have a history of histologically confirmed diagnosis of breast carcinoma or ductal carcinoma in situ, except inflammatory breast cancer. * plan to undergo breast-conserving surgical treatment of breast cancer with curative intent. adjuvant or neoadjuvant chemotherapy is allowed. * have eastern cooperative oncology group (ecog) performance status \<2 * have adequate organ and bone marrow function at screening exclusion criteria: * any known contraindication to ketorolac or other non-steroidal anti-inflammatory drugs (nsaids) * patients anticipated to require the use of a drain after breast-conserving surgery (bcs) * patients undergoing immediate reconstruction surgery, intraoperative radiation therapy (iort) or brachytherapy requiring the placement of balloons or catheters during the lumpectomy procedure.

Keywords: intraoperative ketorolac open-label srg-514 dose escalation immunotherapy
exploring the application efficacy of artificial intelligence (ai) diagnostic tools in medical imaging (mi) of respiratory(r) infectious (i) disease (d)

Conditions: Respiratory Infectious Diseases; Artificial Intelligence; Medical Imaging

Summary: the early identification and severe warning of acute respiratory infectious diseases are of paramount importance. utilizing effective means to make correct diagnoses of the source of infection at an early stage is the premise of all effective measures. ai-mid is a research initiative that uses artificial intelligence tools to assist in the clinical medical imaging diagnosis of respiratory diseases, aiming to reduce the time doctors spend reviewing images, increase work efficiency, and enhance the sensitivity and specificity of pneumonia detection, thereby improving the detection rate of pneumonia at the grassroots level. this approach facilitates precise prevention, accurate diagnosis, and precise treatment.


Eligibility criteria:
inclusion criteria: 1. 1-90 years old, gender not specified. 2. exhibits symptoms of respiratory tract infection 3. must have etiological examination results 4. must have imaging data; exclusion criteria: 1. severe artifacts in medical images 2. clinical diagnosis indicates concurrent pulmonary edema 3. dual review results in unclear diagnosis or potential misdiagnosis 4. other situations that may cause difficulties in reading the films, or as determined by the researcher, the study participant is deemed unsuitable for enrollment.
treatment of plane warts with topical and oral retinoids

Conditions: Plane Warts

Summary: the aim of this study was to compare the effectiveness and safety of topical tretinoin cream 0.05% alone against combination with oral isotretinoin (0.5 mg/kg/day) for treatment of plane warts.

this study included 39 patients divided into two groups. treatment was given for three months duration. patients were followed-up for further three months to assess the recurrence rate. combination treatment led to a faster resolution and a higher percentage of complete response. it presents a promising effective alternative option for treatment of plane warts.

Eligibility criteria:
inclusion criteria: * patients above 12 years diagnosed with plane warts. * patients who had not received any treatment for warts in the last month. exclusion criteria: * pregnancy and lactation. * abnormal lipid profile. * significant hepatic or renal dysfunction. * depression.

Keywords: human papillomavirus tretinoin isotretinoin
the effects of eszopiclone and lexapro on prefrontal glutamate and gaba in depression with anxiety and insomnia

Conditions: Depression; Anxiety; Insomnia

Summary: the study examined the effects of adding the sleep aid eszopiclone to lexapro on mood and levels of the neurotransmitters glutamate, glutamine, and gaba in women with depression, anxiety, and insomnia. specifically, the objective was to determine the role of glutamate, glutamine, and gaba in mediating the response the to the combined treatment. the hypothesis was that levels of glutamine and glutamate will be increased in women receiving eszopiclone compared to those receiving placebo. the antidepressant effect of the medication combination and its effect on sleep status was also assessed.


Eligibility criteria:
inclusion criteria: * female aged 18 to 55 years and regularly menstruating. * meets dsm-iv criteria for unipolar major depression. * insomnia severity index score \> 10. * hamilton anxiety scale score \> 15. * hamilton depression scale score \> 17. * capable of providing informed consent. * has an established residence and phone. exclusion criteria: * meets dsm-iv criteria for schizophrenia, schizoaffective disorder or other axis i or ii diagnosis except co-morbid anxiety disorder and insomnia. * actively abusing substances or alcohol; or has met dsm-iv criteria for substance dependence in the past month. * pregnancy. * use of benzodiazepines or other sedative-hypnotics, beta blockers, calcium channel blockers, antidepressants, antipsychotic medications, lithium or other medication which in the opinion of the investigator could alter glutamate or gaba activity in the brain. * a medical condition, which in the opinion of the investigator could possibly affect the individual's brain levels of glu and gaba. * participation in a research protocol that included administration of medication within the past 3 months. * cigarette smoking. * subject has known allergic sensitivity to any of the study to escitalopram, eszopiclone or zopiclone. * clinically significant suicidal ideation or risk of suicide as evidenced by formulation of a plan or steps taken to act on those feelings. * history of clinically significant hepatic impairment. * subject is taking a potent cytochrome p450 3a4 inhibitor medication (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) and is unwilling or it is clinically contraindicated to stop the medication.

Keywords: magnetic resonance spectroscopy glutamate glutamine gaba lexapro lunesta escitalopram eszopiclone
efficacy and safety of chungkookjang on improvement of metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the investigators performed a 12-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of chungkookjang on improvement of metabolic syndrome. the investigators measured decrement of body fat parameters, including body fat mass, percent body fat, fat free mass, weight and bmi(body mass index), and monitored their blood pressure.


Eligibility criteria:
inclusion criteria: * males and females 18-29 years old * bmi(body mass index) ≥ 23 kg/m2 or wc(waist circumference) ≥ 90(men), wc(waist circumference) ≥ 85(women) * able to give informed consent exclusion criteria: * allergic or hypersensitive to any of the ingredients in the test products * the diagnosis of type 1 and type 2 diabetes or fasting glucose ≥ 126mg/dl * systolic pressure ≥ 160mmhg, diastolic pressure ≥ 100mmhg * history of reaction to any of the test products or of gastrointestinal diseases such as crohn's disease or gastrointestinal surgery * history of alcohol or substance abuse * participation in any other clinical trials within past 2 months * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study